Director/PDMR Shareholding

RNS Number : 9979Z

Oxford BioDynamics PLC

21 December 2017

 

OXFORD BIODYNAMICS PLC

PDMR DEALINGS/EXERCISE OF SHARE OPTIONS

TOTAL VOTING RIGHTS

London, 21 December 2017:  Oxford BioDynamics Plc (AIM: OBD) (the "Company") announces that it has received notices of exercise of options under the Company's 2008 Enterprise Management Incentive Share Option Scheme from Dr Alexandre Akoulitchev, (Chief Scientific Officer) and Dr Aroul Ramadass (Chief Technology Officer) to subscribe for 346,152 and 346,152 Ordinary Shares of 1 pence each in the Company respectively (the "New Ordinary Shares").  The exercise price of the options is 34 pence each.

Following the exercise of these options, Dr Alexandre Akoulitchev owns 6,153,082 Ordinary Shares, representing approximately 7.03% of the Company's enlarged issued share capital, and Dr Aroul Ramadass and family owns 5,830,468 Ordinary Shares, representing approximately 6.66% of the Company's enlarged issued share capital.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on or around 2 January 2018.  The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.

Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 87,479,973 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 87,479,973. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Alexandre Akoulitchev
2	Reason for the notification
a)	Position/status	Chief Scientific Officer/Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Share options exercise
c)	Price(s) and volume(s)	346,152 Ordinary Shares at a price of 34 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	20 December 2017
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Aroul Ramadass
2	Reason for the notification
a)	Position/status	Chief Technology Officer/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Share options exercise
c)	Price(s) and volume(s)	346,152 Ordinary Shares at a price of 34 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	20 December 2017
f)	Place of the transaction	Outside a trading venue

For further details, contact:

Oxford BioDynamics Plc		[phone]
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
Stifel Nicolaus Europe Limited		[phone]
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital		[phone]
Joint Broker
Edward Mansfield
Stephane Auton
FTI Consulting		[phone]
Financial Public Relations Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

DSHLLFEDFILIFID